Drug Profile


Alternative Names: Acomplia; SR 141716; SR 141716A; Zimulti

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi; sanofi-aventis
  • Class Antihyperlipidaemics; Obesity therapies; Piperidines; Pyrazoles; Small molecules; Smoking cessation therapies
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Obesity
  • Market Withdrawal Type 2 diabetes mellitus
  • Discontinued Atherosclerosis; Cardiovascular disorders; Cognition disorders; Hyperlipidaemia; Liver disorders; Neuropathic pain; Schizophrenia; Smoking withdrawal

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 05 Dec 2008 Withdrawn for Obesity in European Union (PO)
  • 05 Dec 2008 Withdrawn for Type-2 diabetes mellitus in European Union (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top